Amphastar Pharmaceuticals (NASDAQ:AMPH) Hits New 1-Year Low – What’s Next?

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)’s stock price hit a new 52-week low on Monday . The stock traded as low as $35.54 and last traded at $35.54, with a volume of 76329 shares trading hands. The stock had previously closed at $36.30.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. Wells Fargo & Company assumed coverage on Amphastar Pharmaceuticals in a research note on Friday, November 22nd. They set an “equal weight” rating and a $55.00 target price on the stock. StockNews.com lowered Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $60.33.

Amphastar Pharmaceuticals Stock Down 1.9 %

The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61. The company has a market cap of $1.71 billion, a PE ratio of 11.87, a price-to-earnings-growth ratio of 0.87 and a beta of 0.82. The company has a fifty day moving average price of $43.95 and a 200 day moving average price of $44.32.

Insider Buying and Selling

In related news, EVP Rong Zhou sold 7,000 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $44.42, for a total transaction of $310,940.00. Following the completion of the transaction, the executive vice president now owns 118,469 shares in the company, valued at $5,262,392.98. This represents a 5.58 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Yakob Liawatidewi sold 5,214 shares of the stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $52.05, for a total value of $271,388.70. Following the completion of the sale, the executive vice president now directly owns 74,938 shares in the company, valued at approximately $3,900,522.90. This represents a 6.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 41,533 shares of company stock worth $1,987,482 in the last quarter. 27.10% of the stock is owned by insiders.

Hedge Funds Weigh In On Amphastar Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its holdings in shares of Amphastar Pharmaceuticals by 70.0% in the 3rd quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock worth $32,000 after purchasing an additional 273 shares during the period. Point72 Asia Singapore Pte. Ltd. lifted its stake in shares of Amphastar Pharmaceuticals by 53.4% during the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company’s stock worth $56,000 after acquiring an additional 398 shares during the last quarter. Asset Management One Co. Ltd. bought a new stake in shares of Amphastar Pharmaceuticals during the 3rd quarter worth approximately $78,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Amphastar Pharmaceuticals by 20.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company’s stock worth $85,000 after acquiring an additional 301 shares during the last quarter. Finally, nVerses Capital LLC lifted its stake in shares of Amphastar Pharmaceuticals by 18.2% during the 3rd quarter. nVerses Capital LLC now owns 2,600 shares of the company’s stock worth $126,000 after acquiring an additional 400 shares during the last quarter. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.